HOME-BASED TREATMENT OF CELLULITIS WITH TWICE-DAILY CEFAZOLIN

Citation
K. Leder et al., HOME-BASED TREATMENT OF CELLULITIS WITH TWICE-DAILY CEFAZOLIN, Medical journal of Australia, 169(10), 1998, pp. 519-522
Citations number
33
Categorie Soggetti
Medicine, General & Internal
ISSN journal
0025729X
Volume
169
Issue
10
Year of publication
1998
Pages
519 - 522
Database
ISI
SICI code
0025-729X(1998)169:10<519:HTOCWT>2.0.ZU;2-7
Abstract
Objective: To assess the clinical outcome and pharmacokinetics of ther apy with cefazolin far patients with cellulitis in a hospital-ill-the- home (HIH) program. Design: Observational study with outcome data comp ared with previously published reports of therapy for cellulitis. Sett ing: A university teaching hospital and HIH unit, July 1996 - December 1997. Participants: Patients with cellulitis were eligible for inclus ion provided their medical condition was stable, they did not require surgical intervention, and their social circumstances allowed home-bas ed therapy. Intervention: Cefazolin 20 intravenously twice daily, with regular nursing and medical assessment. Main outcome measures: Clinic al efficacy; peak and trough serum concentrations of cefazolin. Result s: Fifty-seven patients (37 were men) with a mean age of 48 years (ran ge, 18-90 years) had 61 episodes of moderate to severe cellulitis (41, lower limb; 17, upper limb; and three, face). They received a median of 11 doses of cefazolin (range, 3-27 doses). Clinical outcomes were: cure in 54, improvement in one, treatment failure in three, and in the remaining three episodes the outcome was indeterminate. Cefazolin con centrations were measured in 27 patients. All peak concentrations were more than 40 mu g/mL, while trough concentrations were all above the MIG(90) of the expected pathogens: median, 3.2 mu g/mL (range: 0.4-18. 5 mu g/mL). Cefazolin was well tolerated. Conclusions: Twice-daily cef azolin 20 intravenously is a convenient and effective option for home- based treatment of patients with cellulitis. Its clinical efficacy is comparable with other treatment regimens.